Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 1Recurrence 1Pancreatic Neoplasms 1Nausea 1Multiple Myeloma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Ependymoma 1

Interventions

ruxolitinib 2Methotrexate 2duvelisib 1calaspargase pegol 1Thalidomide 1Prednisone 1Positron-Emission Tomography 1Ifosfamide 1Etoposide 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Large Granular Lymphocytic × Thalidomide × Clear all
NCT06530576 2025-11-18

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡